PMID- 23952463
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20181202
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 67
IP  - 9
DP  - 2013 Sep
TI  - Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and 
      skin structure infections: a meta-analysis of randomised controlled trials.
PG  - 834-42
LID - 10.1111/ijcp.12174 [doi]
AB  - OBJECTIVES: The presumed superiority of moxifloxacin for the treatment of 
      complicated skin and skin structure infections (cSSSIs) is based on laboratory 
      data, but has not yet been established on clinical grounds. The aim of this 
      meta-analysis was to evaluate the efficacy and safety of sequential intravenous 
      (i.v.)/oral (p.o.) moxifloxacin monotherapy for the treatment of cSSSIs. METHODS: 
      Randomised controlled trials (RCTs) published prior to November 2012 were 
      systematically retrieved from PubMed, MEDLINE, EMBASE, ScienceDirect, 
      ClinicalTrials.gov and the Cochrane Central Register of Controlled Trials. 
      Finally, a meta-analysis of all RCTs eligible for inclusion criteria was 
      performed. RESULTS: Three studies that enrolled 2255 patients were included in 
      the meta-analysis. There were no statistically significant differences between 
      patients given moxifloxacin and those given other antibiotics with regard to 
      clinical success rate [1667 patients, odds ratio (OR) = 0.83, 95% confidence 
      interval (CI) 0.63 to 1.09, p = 0.18], bacteriological success rate 
      (bacteriological success rates: 1502 patients, OR = 0.90, 95% CI 0.68-1.18, p = 
      0.45) or mortality (2207 patients, OR = 1.96, 95% CI 0.79-4.88, p = 0.15). 
      Significantly, more overall adverse events (AEs) were associated with the use of 
      moxifloxacin than with other antibiotics (2207 patients, OR = 1.21, 95%CI 
      1.00-1.45, p = 0.04). However, there was no statistically significant difference 
      in the occurrence of drug-related AEs, serious AEs or serious drug-related AEs 
      between patients given moxifloxacin and those given other antibiotics. 
      CONCLUSION: Sequential i.v./p.o. moxifloxacin monotherapy is an effective and 
      relatively safe option for the treatment of cSSSIs. Other benefits of 
      moxifloxacin may make it a more viable option compared with the currently used 
      regimens.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Chen, F
AU  - Chen F
AD  - Department of Pharmacy, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Zheng, N
AU  - Zheng N
FAU - Wang, Y
AU  - Wang Y
FAU - Wen, J L
AU  - Wen JL
FAU - Tu, W F
AU  - Tu WF
FAU - Du, Y Q
AU  - Du YQ
FAU - Lin, J M
AU  - Lin JM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Aza Compounds)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Quinolines)
RN  - U188XYD42P (Moxifloxacin)
SB  - IM
CIN - Int J Clin Pract. 2013 Sep;67(9):820-2. PMID: 23952460
MH  - Administration, Oral
MH  - Anti-Bacterial Agents/*administration & dosage/adverse effects
MH  - Aza Compounds/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Fluoroquinolones
MH  - Humans
MH  - Infusions, Intravenous
MH  - Middle Aged
MH  - Moxifloxacin
MH  - Quinolines/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Skin Diseases, Bacterial/*drug therapy/mortality
MH  - Treatment Outcome
EDAT- 2013/08/21 06:00
MHDA- 2014/01/22 06:00
CRDT- 2013/08/20 06:00
PHST- 2012/12/28 00:00 [received]
PHST- 2013/03/13 00:00 [accepted]
PHST- 2013/08/20 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
AID - 10.1111/ijcp.12174 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2013 Sep;67(9):834-42. doi: 10.1111/ijcp.12174.